Atypical fibroxanthoma: new insights

References

• Helwig EB. Tumor seminar. Tex Med 1963;59:652-89
   Google Scholar
• Kempson RL, McGavran MH. Atypical Fibroxanthomas of the Skin. Cancer 1964;17:1463-71
   PubMed Web of Science ®Google Scholar
• Fretzin DF, Helwig EB. Atypical fibroxanthoma of the skin. A clinicopathologic study of 140 cases. Cancer 1973;31(6):1541-52
   PubMedGoogle Scholar
• Mirza B, Weedon D. Atypical fibroxanthoma: a clinicopathological study of 89 cases. Australas J Dermatol 2005;46(4):235-8
   PubMedGoogle Scholar
• Dahl I. Atypical fibroxanthoma of the skin. A clinico-pathological study of 57 cases. Acta Pathol Microbiol Scand A 1976;84(2):183-97
   PubMedGoogle Scholar
• Rathore D, Mohyudin MN, Mehta P, Ahluwalia HS. Atypical fibroxanthoma of the medial canthus: a rare presentation. Orbit 2013;32(3):194-6
   PubMedGoogle Scholar
• Boynton JR, Markowitch W Jr, Searl SS. Atypical fibroxanthoma of the eyelid. Ophthalmology 1989;96(10):1480-4
   PubMedGoogle Scholar
• Ullrich K, Wells J, Brennan C, Craig J. Recurrent atypical fibroxanthoma of the limbus. BMJ Case Rep 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Lee S, Joo KB, Park CK, et al. A case of atypical fibroxanthoma of subungual type: ultrasound and magnetic resonance imaging findings. Clin Imaging 2013;37(1):155-8
   PubMedGoogle Scholar
• Barbato U, Camera A, Scopelliti G. [A rare case of atypical fibroxanthoma of the lip mucosa: anatomic-clinical and histogenetic considerations]. Ann Stomatol (Roma) 1970;19(8):631-44
   PubMedGoogle Scholar
• Lesica A, Harwood TR, Yokoo H. Atypical fibroxanthoma of ethmoid sinus. Arch Otolaryngol 1975;101(8):506-8
   PubMedGoogle Scholar
• Helwig EB, May D. Atypical fibroxanthoma of the skin with metastasis. Cancer 1986;57(2):368-76
   PubMedGoogle Scholar
• Dettrick A, Strutton G. Atypical fibroxanthoma with perineural or intraneural invasion: report of two cases. J Cutan Pathol 2006;33(4):318-22
   PubMedGoogle Scholar
• Singh RS, Bhattacharjee PB, Youngberg GA, Al-Abbadi MA. Sarcomatoid squamous cell carcinoma: a long-standing case. Acta Dermatovenerol Alp Panonica Adriat 2008;17(4):185-7
   PubMedGoogle Scholar
• Gru AA, Santa Cruz DJ. Atypical fibroxanthoma: a selective review. Semin Diagn Pathol 2013;30(1):4-12
   PubMedGoogle Scholar
• Khan ZM, Cockerell CJ. Atypical fibroxanthoma with osteoclast-like multinucleated giant cells. Am J Dermatopathol 1997;19(2):174-9
   PubMedGoogle Scholar
• Diaz-Cascajo C, Borghi S, Bonczkowitz M. Pigmented atypical fibroxanthoma. Histopathology 1998;33(6):537-41
   PubMedGoogle Scholar
• Orosz Z, Kelemen J, Szentirmay Z. Granular Cell Variant of Atypical Fibroxanthoma. Pathol Oncol Res 1996;2(4):244-7
   PubMedGoogle Scholar
• Crowson AN, Carlson-Sweet K, Macinnis C, et al. Clear cell atypical fibroxanthoma:a clinicopathologic study. J Cutan Pathol 2002;29(6):374-81
   PubMedGoogle Scholar
• Bruecks AK, Medlicott SA, Trotter MJ. Atypical fibroxanthoma with prominent sclerosis. J Cutan Pathol 2003;30(5):336-9
   PubMedGoogle Scholar
• Fussell JN, Cooke ER, Florentino F, Sheehan DJ. Atypical fibroxanthoma with keloidal collagen. Am J Dermatopathol 2010;32(7):713-15
   PubMedGoogle Scholar
• Weedon D, Van Deurse M. Atypical fibroxanthoma. J Cutan Pathol 2012;39(5):565
   PubMedGoogle Scholar
• Thum C, Husain EA, Mulholland K, et al. Atypical fibroxanthoma with pseudoangiomatous features: a histological and immunohistochemical mimic of cutaneous angiosarcoma. Ann Diagn Pathol 2013;17(6):502-7
   PubMedGoogle Scholar
• Singh M, Mann R, Ilankovan V, et al. Atypical fibroxanthoma--a retrospective immunohistochemical study of 42 cases. J Oral Maxillofac Surg 2012;70(11):2713-18
   PubMedGoogle Scholar
• Beer TW. Squamous cell carcinoma with osteoclast-like giant cells: 2 cases misdiagnosed as atypical fibroxanthoma. Am J Dermatopathol 2010;32(4):414-15
   PubMedGoogle Scholar
• Beer TW, Drury P, Heenan PJ. Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases. Am J Dermatopathol 2010;32(6):533-40
   PubMedGoogle Scholar
• Luzar B, Calonje E. Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. J Cutan Pathol 2010;37(3):301-9
   PubMedGoogle Scholar
• Ma CK, Zarbo RJ, Gown AM. Immunohistochemical characterization of atypical fibroxanthoma and dermatofibrosarcoma protuberans. Am J Clin Pathol 1992;97(4):478-83
   PubMedGoogle Scholar
• Sakamoto A, Oda Y, Yamamoto H, et al. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma. Virchows Arch 2002;440(4):404-9
   PubMedGoogle Scholar
• Kanner WA, Brill LB 2nd, Patterson JW, Wick MR. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J Cutan Pathol 2010;37(7):744-50
   PubMedGoogle Scholar
• Monteagudo C, Calduch L, Navarro S, et al. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol 2002;117(1):126-31
   PubMedGoogle Scholar
• Hartel PH, Jackson J, Ducatman BS, Zhang P. CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker. J Cutan Pathol 2006;33(Suppl 2):24-8
   PubMedGoogle Scholar
• Jensen K, Wilkinson B, Wines N, Kossard S. Procollagen 1 expression in atypical fibroxanthoma and other tumors. J Cutan Pathol 2004;31(1):57-61
   PubMedGoogle Scholar
• Sachdev R, Sundram U. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa. J Cutan Pathol 2006;33(5):353-60
   PubMedGoogle Scholar
• Wilk M, Zelger B. Atypical fibroxanthoma - what is it, what it is not. J Cutan Pathol 2010;37(10):1119-20
   PubMedGoogle Scholar
• Smith-Zagone MJ, Prieto VG, Hayes RA, et al. HMB-45 (gp103) and MART-1 expression within giant cells in an atypical fibroxanthoma: a case report. J Cutan Pathol 2004;31(3):284-6
   PubMedGoogle Scholar
• Cuda J, Mirzamani N, Kantipudi R, et al. Diagnostic utility of Fli-1 and D2-40 in distinguishing atypical fibroxanthoma from angiosarcoma. Am J Dermatopathol 2013;35(3):316-18
   PubMedGoogle Scholar
• Cai JP, Randall B. HMB-45 expression in a clear cell variant of atypical fibroxanthoma. J Cutan Pathol 2006;33(2):186-8
   PubMedGoogle Scholar
• Rudisaile SN, Hurt MA, Santa Cruz DJ. Granular cell atypical fibroxanthoma. J Cutan Pathol 2005;32(4):314-17
   PubMedGoogle Scholar
• Miller K, Goodlad JR, Brenn T. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 2012;36(9):1317-26
   PubMedGoogle Scholar
• Griewank KG, Schilling B, Murali R, et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol 2014;27(4):502-8
   PubMedGoogle Scholar
• Hollmig ST, Rieger KE, Henderson MT, et al. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma. Am J Dermatopathol 2013;35(2):176-9
   PubMedGoogle Scholar
• McCalmont TH. AFX: what we now know. J Cutan Pathol 2011;38(11):853-6
   PubMedGoogle Scholar
• McCalmont TH. Correction and clarification regarding AFX and pleomorphic dermal sarcoma. J Cutan Pathol 2012;39(1):8
   PubMedGoogle Scholar
• Matushansky I, Charytonowicz E, Mills J, et al. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century. Expert Rev Anticancer Ther 2009;9(8):1135-44
   PubMed Web of Science ®Google Scholar
• Iorizzo LJ 3rd, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg 2011;37(2):146-57
   PubMedGoogle Scholar
• Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer 1997;79(11):2115-24
   PubMedGoogle Scholar
• Wang YT, Smart CN. Atypical fibrous histiocytoma arising in the perianal area: a case report and review of the literature. Am J Dermatopathol 2014;36(2):171-3
   PubMedGoogle Scholar
• Weng WW, Yang J, Wang J. [Atypical fibrous histiocytoma: a clinicopathologic analysis of 24 cases]. Zhonghua Bing Li Xue Za Zhi 2013;42(5):316-20
   PubMedGoogle Scholar
• Krustrup D, Rossen K, Thomsen HK. Procollagen 1 - a marker of fibroblastic and fibrohistiocytic skin tumors. J Cutan Pathol 2006;33(9):614-18
   PubMedGoogle Scholar
• Hanly AJ, Jorda M, Elgart GW, et al. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors. Arch Pathol Lab Med 2006;130(6):831-4
   PubMedGoogle Scholar
• Gray Y, Robidoux HJ, Farrell DS, Robinson-Bostom L. Squamous cell carcinoma detected by high-molecular-weight cytokeratin immunostaining mimicking atypical fibroxanthoma. Arch Pathol Lab Med 2001;125(6):799-802
   PubMedGoogle Scholar
• Gleason BC, Calder KB, Cibull TL, et al. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma. J Cutan Pathol 2009;36(5):543-7
   PubMedGoogle Scholar
• Chen JT, Hsu JD, Yao CC, et al. Anti-cytokeratin CAM 5.2 does not act as a surrogate of the cytokeratin 8/18 monoclonal antibody. Comment on: "Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma", in J Cutan Pathol 2009; 36: 543. J Cutan Pathol 2010;37(10):1123-4
   PubMedGoogle Scholar
• de Feraudy S, Mar N, McCalmont TH. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma. Am J Surg Pathol 2008;32(8):1111-22
   PubMedGoogle Scholar
• Bull C, Mirzabeigi M, Laskin W, et al. Diagnostic utility of low-affinity nerve growth factor receptor (P 75) immunostaining in atypical fibroxanthoma. J Cutan Pathol 2011;38(8):631-5
   PubMedGoogle Scholar
• Pernick NL, DaSilva M, Gangi MD, et al. “Histiocytic markers” in melanoma. Mod Pathol 1999;12(11):1072-7
   PubMedGoogle Scholar
• Rizzardi C, Angiero F, Melato M. Atypical fibroxanthoma and malignant fibrous histiocytoma of the skin. Anticancer Res 2003;23(2C):1847-51
   PubMedGoogle Scholar
• High AS, Hume WJ, Dyson D. Atypical fibroxanthoma of oral mucosa: a variant of malignant fibrous histiocytoma. Br J Oral Maxillofac Surg 1990;28(4):268-71
   PubMedGoogle Scholar
• Sakamoto A, Oda Y, Itakura E, et al. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma. Mod Pathol 2001;14(6):581-8
   PubMedGoogle Scholar
• Ly H, Selva D, James CL, Huilgol SC. Superficial malignant fibrous histiocytoma presenting as recurrent atypical fibroxanthoma. Australas J Dermatol 2004;45(2):106-9
   PubMedGoogle Scholar
• Marcet S. Atypical fibroxanthoma/malignant fibrous histiocytoma. Dermatol Ther 2008;21(6):424-7
   PubMedGoogle Scholar
• Wick MR, Fitzgibbon J, Swanson PE. Cutaneous sarcomas and sarcomatoid neoplasms of the skin. Semin Diagn Pathol 1993;10(2):148-58
   PubMedGoogle Scholar
• Oshiro Y, Fukuda T, Tsuneyoshi M. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining. Cancer 1995;75(5):1128-34
   PubMedGoogle Scholar
• Worrell JT, Ansari MQ, Ansari SJ, Cockerell CJ. Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications. J Cutan Pathol 1993;20(3):211-15
   PubMedGoogle Scholar
• Sakamoto A, Oda Y, Itakura E, et al. H-, K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Hum Pathol 2001;32(11):1225-31
   PubMedGoogle Scholar
• Longacre TA, Smoller BR, Rouse RV. Atypical fibroxanthoma. Multiple immunohistologic profiles. Am J Surg Pathol 1993;17(12):1199-209
   PubMedGoogle Scholar
• Dei Tos AP, Maestro R, Doglioni C, et al. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol 1994;145(1):11-17
   PubMedGoogle Scholar
• Dilek FH, Akpolat N, Metin A, Ugras S. Atypical fibroxanthoma of the skin and the lower lip in xeroderma pigmentosum. Br J Dermatol 2000;143(3):618-20
   PubMedGoogle Scholar
• Sakamoto A, Akieda S, Oda Y, et al. Mutation analysis of the Gadd45 gene at exon 4 in atypical fibroxanthoma. BMC Dermatol 2009;9:1
   PubMedGoogle Scholar
• Bandyopadhyay R, Nag D, Bandyopadhyay S, Sinha SK. Atypical fibroxanthoma: an unusual skin neoplasm in xeroderma pigmentosum. Indian J Dermatol 2012;57(5):384-6
   PubMedGoogle Scholar
• Andres C, Puchta U, Flaig MJ. Detection of Merkel cell polyomavirus DNA in atypical fibroxanthoma in correlation to clinical features. Am J Dermatopathol 2010;32(8):799-803
   PubMedGoogle Scholar
• Andres C, Puchta U, Sander CA, et al. Prevalence of Merkel cell polyomavirus DNA in cutaneous lymphomas, pseudolymphomas, and inflammatory skin diseases. Am J Dermatopathol 2010;32(6):593-8
   PubMedGoogle Scholar
• Zur Hausen A. [Merkel cell polyomavirus in the pathogenesis of non-melanoma skin cancer]. Pathologe 2009;30(Suppl 2):217-20
   PubMedGoogle Scholar
• Foulongne V, Dereure O, Kluger N, et al. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol 2010;162(1):59-63
   PubMed Web of Science ®Google Scholar
• Hafner J, Kunzi W, Weinreich T. Malignant fibrous histiocytoma and atypical fibroxanthoma in renal transplant recipients. Dermatology 1999;198(1):29-32
   PubMedGoogle Scholar
• Ferri E, Iaderosa GA, Armato E. Atypical fibroxanthoma of the external ear in a cardiac transplant recipient: case report and the causal role of the immunosuppressive therapy. Auris Nasus Larynx 2008;35(2):260-3
   PubMedGoogle Scholar
• Perrett CM, Macedo C, Francis N, et al. Atypical fibroxanthoma in an HIV-infected individual. J Cutan Pathol 2011;38(4):357-9
   PubMedGoogle Scholar
• Colgan MB, Brewer JD, Weaver AL, et al. Atypical fibroxanthoma in the setting of chronic lymphocytic leukemia and other non-Hodgkin lymphomas. Dermatol Surg 2011;37(5):671-6
   PubMedGoogle Scholar
• Avshalumov K, Williford P, Sangueza OP, Goldenberg G. Atypical fibroxanthoma presenting in a patient with stage III mycosis fungoides. J Dermatolog Treat 2008;19(2):118-20
   PubMed Web of Science ®Google Scholar
• Tchernev G, Tronnier M, Ananiev J, et al. Atypical fibroxanthoma-a diagnosis of exclusion!. Wien Med Wochenschr 2013;163(15-16):380-6
   PubMedGoogle Scholar
• Vargas-Cortes F, Winkelmann RK, Soule EH. Atypical fibroxanthomas of the skin. Further observations with 19 additional cases. Mayo Clinic proceedings 1973;48(3):211-8
   PubMedGoogle Scholar
• Barr RJ, Wuerker RB, Graham JH. Ultrastructure of atypical fibroxanthoma. Cancer 1977;40(2):736-43
   PubMedGoogle Scholar
• Alguacil-Garcia A, Unni KK, Goellner JR, Winkelmann RK. Atypical fibroxanthoma of the skin: an ultrastructural study of two cases. Cancer 1977;40(4):1471-80
   PubMedGoogle Scholar
• Mihic-Probst D, Zhao J, Saremaslani P, et al. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. Anticancer Res 2004;24(1):19-26
   PubMedGoogle Scholar
• Phelps RG, Bernstein LE, Harpaz N, et al. Characterization of a dermal derived malignant mesenchymal tumor arising in ultraviolet irradiated mice. Am J Pathol 1989;135(1):149-59
   PubMedGoogle Scholar
• McCalmont TH, Scheinberg RS. AFX ex BFX. J Cutan Pathol 2011;38(5):387-90
   PubMedGoogle Scholar
• Hussein MR. Genetic pathways to melanoma tumorigenesis. J Clin Pathol 2004;57(8):797-801
   PubMed Web of Science ®Google Scholar
• Pincus LB, McCalmont TH, Neuhaus IM, et al. Basal cell carcinomas arising within multiple trichoepitheliomas. J Cutan Pathol 2008;35(Suppl 1):59-64
   PubMedGoogle Scholar
• Gouiaa N, Abbes K, Fakhfekh I, et al. [Hidradenocarcinoma arising from pre-existing hidradenoma]. Ann Dermatol Venereol 2008;135(10):714-15
   PubMedGoogle Scholar
• Hui P, Glusac EJ, Sinard JH, Perkins AS. Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma). J Cutan Pathol 2002;29(7):385-9
   PubMedGoogle Scholar
• Smith KJ, Skelton HG 3rd, Morgan AM, et al. Spindle cell neoplasms coexpressing cytokeratin and vimentin (metaplastic squamous cell carcinoma). J Cutan Pathol 1992;19(4):286-93
   PubMedGoogle Scholar
• Nakamura M, Sugita K, Tokura Y. Expression of Snail1 in the vimentin-expressing squamous cell carcinoma mimicking atypical fibroxanthoma: possible involvement of an epithelial-mesenchymal transition. J Eur Acad Dermatol Venereol 2010;24(11):1365-6
   PubMedGoogle Scholar
• Hyatt AM, Mutasim DF, Spicknall KE. Collision of atypical fibroxanthoma and acantholytic squamous cell carcinoma in situ. Am J Dermatopathol 2012;34(5):563-4
   PubMedGoogle Scholar
• Eckert F, Schaich B, Landthaler M. [Spinocellular cancers and myxoid atypical fibroxanthoma of an actinically damaged burn scar]. Hautarzt 1991;42(4):254-7
   PubMedGoogle Scholar
• Ergun SS, Buyukbabani N, Su O. Atypical fibroxanthoma in a chronic burn scar of the cheek. J Dermatol 2011;38(10):1000-3
   PubMedGoogle Scholar
• Hiscutt EL, Adams JR, Ryan JM, et al. Atypical fibroxanthoma, lentigo maligna melanoma and squamous cell carcinoma arising in the site of a thermal burn treated with skin grafts. Br J Oral Maxillofac Surg 2009;47(2):157-8
   PubMedGoogle Scholar
• Bansal C, Sinkre P, Stewart D, Cockerell CJ. Two cases of cytokeratin positivity in atypical fibroxanthoma. J Clin Pathol 2007;60(6):716-17
   PubMedGoogle Scholar
• Suarez-Vilela D, Izquierdo FM, Escobar-Stein J, Mendez-Alvarez JR. Atypical fibroxanthoma with T-cytotoxic inflammatory infiltrate and aberrant expression of cytokeratin. J Cutan Pathol 2011;38(11):930-2
   PubMedGoogle Scholar
• Hussein MR, Al-Badaiwy ZH, Guirguis MN. Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic keratinocytic hyperproliferative lesions. J Cutan Pathol 2004;31(10):643-51
   PubMedGoogle Scholar
• Rashad UM, Hussein MR, Algizawy SM. Alterations of p53 and Bcl-2 protein expression in the recurrent laryngeal and pharyngeal squamous cell carcinoma. Am J Otolaryngol 2011;32(3):210-14
   PubMedGoogle Scholar
• Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2(6):442-54
   PubMed Web of Science ®Google Scholar
• Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7(2):131-42
   PubMed Web of Science ®Google Scholar
• Lyons JG, Lobo E, Martorana AM, Myerscough MR. Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis 2008;25(6):665-77
   PubMedGoogle Scholar
• Hussein MR. Transforming growth factor-beta and malignant melanoma: molecular mechanisms. J Cutan Pathol 2005;32(6):389-95
   PubMed Web of Science ®Google Scholar
• Imajyo I, Sugiura T, Kobayashi Y, et al. T-box transcription factor Brachyury expression is correlated with epithelial-mesenchymal transition and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol 2012;41(6):1985-95
   PubMedGoogle Scholar
• Tsai JH, Donaher JL, Murphy DA, et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012;22(6):725-36
   PubMed Web of Science ®Google Scholar
• Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 2013;27(20):2192-206
   PubMed Web of Science ®Google Scholar
• Yu C, Liu Y, Tan H, et al. Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signalling pathway-mediated epithelial-mesenchymal transition. Cancer Lett 2014;343(2):258-67
   PubMed Web of Science ®Google Scholar
• Ding XM. MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer 2014;33(3):140-7
   PubMedGoogle Scholar
• Ang GC, Roenigk RK, Otley CC, et al. More than 2 decades of treating atypical fibroxanthoma at mayo clinic: what have we learned from 91 patients? Dermatol Surg 2009;35(5):765-72
   PubMedGoogle Scholar
• Zalla MJ, Randle HW, Brodland DG, et al. Mohs surgery vs wide excision for atypical fibroxanthoma: follow-up. Dermatol Surg 1997;23(12):1223-4
   PubMedGoogle Scholar
• Dudelzak J, Sheehan DJ, Mullins SC, Peterson CM. Malignant perifollicular atypical fibroxanthoma treated with Mohs surgery. Dermatol Surg 2007;33(3):364-8
   PubMedGoogle Scholar
• Limmer BL, Clark DP. Cutaneous micrographic surgery for atypical fibroxanthoma. Dermatol Surg 1997;23(7):553-7. discussion 557-558
   PubMedGoogle Scholar
• Wollina U, Schonlebe J, Koch A, Haroske G. Atypical fibroxanthoma: a series of 25 cases. J Eur Acad Dermatol Venereol 2010;24(8):943-6
   PubMedGoogle Scholar
• Davis JL, Randle HW, Zalla MJ, et al. A comparison of Mohs micrographic surgery and wide excision for the treatment of atypical fibroxanthoma. Dermatol Surg 1997;23(2):105-10
   PubMedGoogle Scholar
• Seavolt M, McCall M. Atypical fibroxanthoma: review of the literature and summary of 13 patients treated with Mohs micrographic surgery. Dermatol Surg 2006;32(3):435-41. discussion 439-441
   PubMedGoogle Scholar
• Satter EK. Metastatic atypical fibroxanthoma. Dermatol Online J 2012;18(9):3
   Google Scholar
• Weedon D, Kerr JF. Atypical fibroxanthoma of skin: an electron microscope study. Pathology 1975;7(3):173-7
   PubMed Web of Science ®Google Scholar
• Giuffrida TJ, Kligora CJ, Goldstein GD. Localized cutaneous metastases from an atypical fibroxanthoma. Dermatol Surg 2004;30(12 Pt 2):1561-4
   PubMedGoogle Scholar
• Jacobs DS, Edwards WD, Ye RC. Metastatic atypical fibroxanthoma of skin. Cancer 1975;35(2):457-63
   PubMedGoogle Scholar
• Grosso M, Lentini M, Carrozza G, Catalano A. Metastatic atypical fibroxanthoma of skin. Pathol Res Pract 1987;182(3):443-7
   PubMedGoogle Scholar
• Muenster MR, Hoang MP. Left facial mass in an elderly man. Metastasizing atypical fibroxanthoma of the skin. Arch Pathol Lab Med 2006;130(5):735-6
   PubMedGoogle Scholar
• Lum DJ, King AR. Peritoneal metastases from an atypical fibroxanthoma. Am J Surg Pathol 2006;30(8):1041-6
   PubMedGoogle Scholar
• Rosenbluth JM, Johnson K, Tang L, et al. Evaluation of p63 and p73 antibodies for cross-reactivity. Cell cycle 2009;8(22):3702-6
   PubMed Web of Science ®Google Scholar
• Clarke LE, Frauenhoffer E, Fox E, et al. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma. J Cutan Pathol 2010;37(7):737-43
   PubMedGoogle Scholar
• Hultgren TL, DiMaio DJ. Immunohistochemical staining of CD10 in atypical fibroxanthomas. J Cutan Pathol 2007;34(5):415-19
   PubMedGoogle Scholar
• Ricci A Jr, Cartun RW, Zakowski MF. Atypical fibroxanthoma. A study of 14 cases emphasizing the presence of Langerhans’ histiocytes with implications for differential diagnosis by antibody panels. Am J Surg Pathol 1988;12(8):591-8
   PubMedGoogle Scholar